IRBM is attending EPS 2026 in Vienna to explore what's possible when great peptide programs meet the right capabilities.
Published
Signal category
Presence & Recognition
Quote
“We’re heading to EPS 2026 in Vienna with new science, new ideas, and one goal: exploring what’s possible when great peptide programs meet the right capabilities.”
— Ali Hoseini, PhD, MBA|IRBM team
Company
IRBM
#IRBM — powerful integrated drug discovery from concept to candidate.
- Industry
- Biotechnology Research
- Location
- Pomezia, IT
- Company size
- 280 employees
IRBM is a scientific contract research organization (CRO) that stands at the forefront of drug discovery, leveraging a single, unified research facility to accelerate team-based breakthroughs and improve efficiencies from concept to candidate. With a history of contributing to several approved drugs, and its own internal pipeline of oncology and other therapeutic assets, IRBM is powered by deep collaborations and decades of expertise from leading global institutions. Their comprehensive in-house capabilities assist partners in achieving key milestones and progressing towards clinical readiness, positioning IRBM as a major player in driving innovation in the pharmaceutical and biotech fields. Find more detailed information available on our website below.
Founded 2009